Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical trial evidence from the ARASENS trial demonstrates that darolutamide plus ADT and docetaxel significantly improves overall survival compared to placebo plus ADT and docetaxel, with a hazard ratio of 0.68. This indicates a clear clinical advantage, although the evidence is based on a single Phase 3 trial. This strengthens the market access risk assessment and overall reimbursement probability.
Cost effectiveness
The cost-effectiveness estimates for darolutamide are within what NICE considers acceptable for Healthcare resources, with the committee concluding that it is an acceptable use of resources. The confidential commercial arrangement further supports its cost-effectiveness. This informs pricing and reimbursement risk and pharmaceutical reimbursement forecasting.
Quality of life
The ARASENS trial did not collect EQ-5D data, and the HRQoL estimates were derived from other studies. While the committee concluded that the utility values used were appropriate, the lack of direct HRQoL data from the trial limits the strength of the evidence. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Supporting Domains
Safety and Adverse Effects
Darolutamide plus ADT and docetaxel was reported to be well tolerated, with only mild to moderate adverse events noted. The committee highlighted that the treatment did not significantly impact daily activities, indicating a favorable safety profile. This profile reduces payer uncertainty and supports access risk forecasting.
Comparator Selection
The comparators selected for the evaluation (ADT alone, ADT with docetaxel, and ADT with enzalutamide) are relevant and reflect current clinical practice. The committee agreed with the appropriateness of these comparators. This aligns with HTA comparator analysis and strengthens the market access submission.
Patient Population and Subgroups
The ARASENS trial included a diverse population, although there were fewer participants from Black or African American backgrounds compared to Healthcare clinical practice. The committee concluded that the trial population was generally representative. This enhances reimbursement likelihood rating and payer relevance.
Care Pathway Integration
Darolutamide can be integrated into existing treatment pathways for hormone-sensitive metastatic prostate cancer with minor adjustments. The committee noted that it fits well within the current treatment landscape. This supports budget impact analysis and facilitates market access feasibility.
Resource Use and Cost Implications
The resource implications of darolutamide are manageable and aligned with Healthcare planning. The committee noted that the budget impact is acceptable, although it may require monitoring. This supports pricing model stress-testing and payer evidence expectations.
Evidence Quality and Robustness
The evidence base is supported by a robust Phase 3 RCT (ARASENS) with a large sample size, although there are some limitations regarding the generalizability of certain demographic groups. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Uncertainty, Sensitivity, and Broader Impacts
There are some uncertainties regarding the long-term effectiveness and cost-effectiveness estimates, particularly concerning treatment-effect waning and the impact of confidential discounts. The committee acknowledged these uncertainties but deemed them manageable. These factors elevate access risk forecasting within HTA evaluation frameworks.
